Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 6,760 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CHANGE Study Clear all

Conditions: Vehicular Environment
Interventions: HEPA air purifier, questionnaires, Log-book, Urine sample; Device · Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 90 Years · Male only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Danuglipron, Cyclosporine, Itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Restless Leg Syndrome
Interventions: Gabapentin immediate release, Gabapentin enacarbil extended release; Drug
Lead sponsor: Theresa Zesiewicz, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Marijuana Dependence
Interventions: Standard CBT, CBT+CM/adherence, CM/abstinence, CM/abstinence+CBT; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Caregivers, Burnout, Sleep
Interventions: Mindfulness Training, Reappraisal Training; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Prostate Disease
Interventions: Plastic Scintillation Detectors; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Autism, Asperger's Syndrome, Generalized Anxiety Disorder, Social Phobia, Separation Anxiety Disorder, Obsessive-compulsive Disorder
Interventions: Cognitive-behavioral therapy, Treatment as Usual; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 7 Years to 11 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Emphysema, Alpha 1-antitrypsin Deficiency (AATD)
Interventions: Prolastin-C, 60 mg/kg, Prolastin-C, 120 mg/kg; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Gainesville, Florida • Miami, Florida • Philadelphia, Pennsylvania + 2 more

Conditions: Temporomandibular Joint Dysfunction Syndrome
Interventions: PACT Experimental Arm; Behavioral
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Obesity, Smoking Cessation, Bariatric Surgery Patients
Interventions: Naltrexone hydrochloride, Bupropion Hydrochloride Extended-release, Cognitive-Behavioral Therapy; Drug · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Metastatic Breast Cancer
Interventions: biomarker study; Other
Lead sponsor: Side-Out Foundation; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Miami, Florida + 4 more

Conditions: Anxiety Symptoms, Depressive Symptoms
Interventions: Implicit Theories of Personality Program, Control Program; Other
Lead sponsor: Harvard University; Other
Eligibility: 12 Years to 15 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions: Conditioning and Stem cell infusion; Combination Product
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cervical Ripening, Labor, Induced
Interventions: Misoprostol vaginal insert 100 mcg, Misoprostol vaginal insert 50 mcg, Dinoprostone vaginal insert (Cervidil); Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 49
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 43 more

Conditions: Breast Cancer Risk
Interventions: Breast Cancer Risk Reduction Household Intervention; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 10 Years to 65 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Knee Osteoarthritis
Interventions: inulin, Maltodextrin (Placebo); Drug
Lead sponsor: Yale University; Other
Eligibility: 40 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Headache
Interventions: Osteopathic Manipulative Treatment, Sham Osteopathic Manipulative Treatment; Procedure
Lead sponsor: Good Samaritan Hospital Medical Center, New York; Other
Eligibility: 21 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: West Islip, New York

Conditions: Nonalcoholic Fatty Liver Disease
Interventions: Dietary modification; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 11 Years to 16 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: San Diego, California • Atlanta, Georgia

Conditions: Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Interventions: LOXO-260; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 10 more

Conditions: Surgical Patients
Interventions: Observation; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Year and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Tafasitamab, Vincristine; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fibromyalgia, Veterans
Interventions: ReSeT-FM intervention; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Postpartum Bladder Dysfunction, Post-prostatectomy Bladder Dysfunction, Bladder Dysfunction
Interventions: DFree Non-Invasive Bladder Ultrasound, Perifit Kegel Exerciser, Exit interview; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules, Placebo Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Little Rock, Arkansas • Lemon Grove, California • Long Beach, California + 9 more

Search by objective public record fields.

DRIIVE (Data and Research on Interventions to Improve the Vehicular Environment)

A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.

Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome

Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management

Eudaimonia and Sleep: Effects of a Mindfulness Intervention in Caregivers of People With Dementia

In Vivo Dosimetry During Prostate Cancer Radiotherapy

Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency

Tailored Self-Management of Temporomandibular Disorders (TMD) Using Health Information Technology

A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer

Effects of a Single-session Implicit Theories of Personality Intervention on Early Adolescent Psychopathology

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor

Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition

Inulin Supplementation for Reducing Inflammation and Knee Pain in Older Adults With Osteoarthritis

Will the Use of Osteopathic Manipulative Treatments Help Alleviate Headache Pain

Dietary Treatment Study of Pediatric NAFLD

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

Heart Rate Changes With Propofol

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Reducing Sedentary Time in Fibromyalgia Patients

Exploring Clinical Utility of Wearables for the Bladder in Pelvic Health Physical Therapy Clinics

A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia